Ascentage Pharma Group International (AAPG) Stock Price, News & Analysis

Company Overview

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying.

The company's two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Its pipeline also includes alrizomadlin (APG-115), an investigational cancer treatment, and additional drug candidates targeting pathways involved in cancer cell survival.

Ascentage conducts research and clinical-development activities in China and internationally, including in the United States. While some of its drugs are already approved in China, others remain subject to clinical testing and regulatory review, and approved uses may vary by geography. The company's American Depositary Shares trade on the Nasdaq Global Market under the symbol AAPG, while its ordinary shares are listed on the Hong Kong Stock Exchange under stock code 6855.

Key Stats

• Today's Range: $14.83 to $15.50
• 50-Day Range: $14.55 to $18.99
• 52-Week Range: $14.45 to $37.50
• Volume: 6,719 shs
• Average Volume: 6,819 shs
• Market Capitalization: $1.42 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.67
• Consensus Rating: Buy

Ascentage Pharma Group International Stock Analysis - MarketRank™

Ascentage Pharma Group International scored higher than 83% of companies evaluated by MarketBeat, and ranked 113th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Buy

Consensus Rating

Ascentage Pharma Group International has received a consensus rating of Buy. The company's average rating score is 3.15, and is based on 2 strong buy ratings, 11 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Ascentage Pharma Group International has a consensus price target of $43.67, representing about 182.6% upside from its current price of $15.45.

Amount of Analyst Coverage

Ascentage Pharma Group International has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ascentage Pharma Group International are expected to grow in the coming year, from ($2.42) to $0.02 per share.

Price to Book Value per Share Ratio

Ascentage Pharma Group International has a P/B Ratio of 7.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Ascentage Pharma Group International has been sold short.

Short Interest Ratio / Days to Cover

Ascentage Pharma Group International has a short interest ratio ("days to cover") of 1.48, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ascentage Pharma Group International has recently decreased by 53.43%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ascentage Pharma Group International does not currently pay a dividend.

Dividend Growth

Ascentage Pharma Group International does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.27

News Sentiment

Ascentage Pharma Group International has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Ascentage Pharma Group International this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 3 people have added Ascentage Pharma Group International to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ascentage Pharma Group International insiders have not sold or bought any company stock.

Percentage Held by Institutions

Ascentage Pharma Group International has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/19/2026
• Today: 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AAPG
• Previous Symbol: NASDAQ:AAPG
• CIK: 2023311
• Web: www.ascentage.com
• Phone: 86 512 8555 7777
• Fax: N/A
• Employees: 767
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Ascentage Pharma Group International: $43.67
• High Price Target: $51.00
• Low Price Target: $33.00
• Potential Upside/Downside: +187.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.15
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.09
• Current Ratio: 1.22
• Quick Ratio: 1.18

Sales & Book Value

• Annual Sales: $82.10 million
• Price / Sales: 17.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.04 per share
• Price / Book: 7.45

Miscellaneous

• Outstanding Shares: 93,400,000
• Free Float: N/A
• Market Cap: $1.42 billion
• Optionable: N/A
• Beta: 0.12